Abstract
Angiotensin-I converting enzyme (ACE) has an important function in blood pressure regulation. ACEinhibitory peptides can lower blood pressure by inhibiting ACE activity. In this investigation, water-soluble proteins were extracted from yeast (Saccharomyces cerevisiae) and hydrolyzed by yeast protein extraction enzyme to isolate ACEinhibitory peptides. Peptides with ACE-inhibitory activity were further separated and purified by ultrafiltration and fast protein liquid chromatography (FPLC). A hexapeptide, Thr-Pro-Thr-Gln-Gln-Ser, with a calculated molecular weight of 660Da, was purified and identified by MALDI-TOF-MS. The hexapeptide showed remarkable ACE-inhibitory activity, with an IC50 of 73.25 μg/mL. The level of ACE-inhibitory activity of the hexapeptide indicated that it is a good candidate for development of a hypotension drug or functional food.
Keywords: Angiotensin-I converting enzyme, Bioactive peptide, Inhibitory peptide, Yeast protein, Fast protein liquid chromatography (FPLC), High performance liquid chromatography, Mass spectrometry, MALDI-TOF-MS, Ultrafiltration, Water-soluble proteins
Current Analytical Chemistry
Title: Isolation and Identification of an Angiotensin-I Converting Enzyme Inhibitory Peptide from Yeast (Saccharomyces cerevisiae)
Volume: 8 Issue: 1
Author(s): He Ni, Lin Li, Sha-Sha Guo, Hai-Hang Li, Rui Jiang and Song-Qing Hu
Affiliation:
Keywords: Angiotensin-I converting enzyme, Bioactive peptide, Inhibitory peptide, Yeast protein, Fast protein liquid chromatography (FPLC), High performance liquid chromatography, Mass spectrometry, MALDI-TOF-MS, Ultrafiltration, Water-soluble proteins
Abstract: Angiotensin-I converting enzyme (ACE) has an important function in blood pressure regulation. ACEinhibitory peptides can lower blood pressure by inhibiting ACE activity. In this investigation, water-soluble proteins were extracted from yeast (Saccharomyces cerevisiae) and hydrolyzed by yeast protein extraction enzyme to isolate ACEinhibitory peptides. Peptides with ACE-inhibitory activity were further separated and purified by ultrafiltration and fast protein liquid chromatography (FPLC). A hexapeptide, Thr-Pro-Thr-Gln-Gln-Ser, with a calculated molecular weight of 660Da, was purified and identified by MALDI-TOF-MS. The hexapeptide showed remarkable ACE-inhibitory activity, with an IC50 of 73.25 μg/mL. The level of ACE-inhibitory activity of the hexapeptide indicated that it is a good candidate for development of a hypotension drug or functional food.
Export Options
About this article
Cite this article as:
Ni He, Li Lin, Guo Sha-Sha, Li Hai-Hang, Jiang Rui and Hu Song-Qing, Isolation and Identification of an Angiotensin-I Converting Enzyme Inhibitory Peptide from Yeast (Saccharomyces cerevisiae), Current Analytical Chemistry 2012; 8 (1) . https://dx.doi.org/10.2174/157341112798472224
DOI https://dx.doi.org/10.2174/157341112798472224 |
Print ISSN 1573-4110 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6727 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Heart in Sepsis: From Basic Mechanisms to Clinical Management
Current Vascular Pharmacology Endothelial Dysfunction Induced by Cadmium and Mercury and its Relationship to Hypertension
Current Hypertension Reviews The Vascular Endothelin System in Hypertension - Recent Patents and Discoveries
Recent Patents on Cardiovascular Drug Discovery Role of Renin Angiotensin System Inhibitors in Cardiovascular and Renal Protection: A Lesson from Clinical Trials
Current Pharmaceutical Design Machine Learning Approaches in Parkinson’s Disease
Current Medicinal Chemistry Beta-Blocking Agents and Electroconvulsive Therapy
Current Drug Therapy The Secretin/Pituitary Adenylate Cyclase-Activating Polypeptide/ Vasoactive Intestinal Polypeptide Superfamily in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Novel Strategies in Cancer Therapeutics: Targeting Enzymes Involved in Cell Cycle Regulation and Cellular Proliferation
Current Cancer Drug Targets Cytochrome P450s: Mechanisms and Biological Implications in Drug Metabolism and its Interaction with Oxidative Stress
Current Drug Metabolism Refractory Behçet’s Disease with Multi-organ Involvement - Learning from Failure
Current Rheumatology Reviews Phenomenology and Neurobiology of Childhood Onset Schizophrenia
Current Psychiatry Reviews Monoclonal Antibodies in Rare Acquired Thrombotic Disorders: The Paradigms of Paroxysmal Nocturnal Hemoglobinuria, Thrombotic Thrombocytopenic Purpura and Central Retinal Vein Occlusion
Current Vascular Pharmacology Potential Beneficial Effects of Garlic in Oncohematology
Mini-Reviews in Medicinal Chemistry Critical Questions for Preclinical Trials on Safety and Efficacy of Vascular Endothelial Growth Factor-Based Therapeutic Angiogenesis for Ischemic Stroke
CNS & Neurological Disorders - Drug Targets Management of the Low Cardiac Output Syndrome Following Surgery for Congenital Heart Disease
Current Cardiology Reviews Blood Pressure Control and Diabetic Retinopathy
Current Hypertension Reviews Long Term Cardiovascular Risk in Women
Vascular Disease Prevention (Discontinued) Renin-Angiotensin-Aldosterone System in Autosomal Dominant Polycystic Kidney Disease
Current Hypertension Reviews A2A Receptor Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry Mechanisms Involved in Apoptosis Events Contributing to Sepsis-Induced Myocardial Dysfunction
Current Drug Therapy